Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/ PALB2 mutation

Eileen M. O’Reilly*, Jonathan W. Lee, Mark Zalupski, Marinela Capanu, Jennifer Park, Talia Golan, Esther Tahover, Maeve A. Lowery, Joanne F. Chou, Vaibhav Sahai, Robin Brenner, Hedy L. Kindler, Kenneth H. Yu, Alice Zervoudakis, Shreya Vemuri, Zsofia K. Stadler, Richard K.G. Do, Neesha Dhani, Alice P. Chen, David P. Kelsen

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

252 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/ PALB2 mutation'. Together they form a unique fingerprint.

Medicine & Life Sciences